BIOLINERX LTD. ADS overview

BioLineRx Reports 2024 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, March 31, 2025 - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings...

BioLineRx to Report 2024 Annual Results on March 31, 2025 PR Newswire TEL AVIV, Israel, March 24, 2025 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025 , before the...

BioLineRx Issues Letter to Shareholders PR Newswire TEL AVIV, Israel, Jan. 21, 2025 - Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders. To my fellow shareholders, It has been approximately two months since we announced a major...

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares PR Newswire TEL AVIV, Israel, Jan. 17, 2025 TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New...

BioLineRx Announces $10 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, Jan. 6, 2025 TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or...

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value PR Newswire TEL AVIV, Israel, Nov. 25, 2024 - Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and...

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. PR Newswire TEL AVIV, Israel, Nov. 21, 2024 – BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –...

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 PR Newswire TEL AVIV, Israel, Nov. 20, 2024 Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday,...